0001415889-24-017005.txt : 20240614 0001415889-24-017005.hdr.sgml : 20240614 20240614180149 ACCESSION NUMBER: 0001415889-24-017005 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240612 FILED AS OF DATE: 20240614 DATE AS OF CHANGE: 20240614 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Booth Bruce CENTRAL INDEX KEY: 0001451612 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39460 FILM NUMBER: 241046297 MAIL ADDRESS: STREET 1: 890 WINTER STREET STREET 2: SUITE 320 CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Kymera Therapeutics, Inc. CENTRAL INDEX KEY: 0001815442 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 812992166 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 500 NORTH BEACON STREET, 4TH FLOOR CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 857-285-5314 MAIL ADDRESS: STREET 1: 500 NORTH BEACON STREET, 4TH FLOOR CITY: WATERTOWN STATE: MA ZIP: 02472 4 1 form4-06142024_100645.xml X0508 4 2024-06-12 0001815442 Kymera Therapeutics, Inc. KYMR 0001451612 Booth Bruce C/O KYMERA THERAPEUTICS, INC. 200 ARSENAL YARDS BLVD., SUITE 230 WATERTOWN MA 02472 true false false false 1 Common Stock 2024-06-12 4 S 0 11838 35.35 D 4558827 I See footnote Common Stock 2024-06-12 4 S 0 1997 36.02 D 4556830 I See footnote Common Stock 2024-06-12 4 S 0 2485 35.35 D 804212 I See footnote Common Stock 2024-06-12 4 S 0 420 36.02 D 803792 I See footnote Common Stock 2024-06-13 4 S 0 8430 34.98 D 4548400 I See footnote Common Stock 2024-06-13 4 S 0 1770 34.98 D 802022 I See footnote This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. on January 22, 2024. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.95 to $35.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4) and (7). These shares are held directly by Atlas Venture Fund X, L.P. ("Atlas Venture Fund X"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. ("AVA X LP"). Atlas Venture Associates X, LLC ("AVA X LLC") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extend of his pecuniary interest therein, if any. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.99 to $36.29 inclusive. This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Opportunity Fund I, L.P. on January 22, 2024. The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. ("AVOF I"). Atlas Venture Associates Opportunity I, L.P. ("AVAO LP") is the general partner of AVOF I. Atlas Venture Associates Opportunity I, LLC ("AVAO LLC") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF I, except to the extent of his pecuniary interest therein, if any. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.95 to $34.985 inclusive. /s/ Ommer Chohan, Attorney-in-Fact 2024-06-14